2. Praluent. https://www.praluent.com/ Retrieved on 05, 04, 2023.3. Leviq. https://www.leqvio.com/ Retrieved on 05, 04, 2023.4. Ballantyne, C. M. et al. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial. J Am Coll Cardiol. Ma...
2. https://www.businesswire.com/news/home/20230306005288/en/Merck%E2%80%99s-MK-0616-an-Investigational-Oral-PCSK9-Inhibitor-Significantly-Reduced-LDL-C-in-Patients-with-Hypercholesterolemia-in-Phase-2b-Study?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork 3. https://www.jacc...
MK-0616 was generally well tolerated and reduced LDL-C across all dose levels compared to placebo MSD plans to start Phase 3 pivotal study in the second half of 2023 RAHWAY, N.J., March 6, 2023 – MSD (tradename of Merck & Co., Inc., Ra...
MK-0616是一类大环肽类药物,是通过mRNA展示技术筛选出的一种多肽(图2),和PCSK9有很高的亲和性(图3)。在其Ⅰ期临床研究中,发现MK-0616用药2周后能降低血浆PCSK9水平达93%;在他汀治疗的基础上,能降低LDL-C最高达61% [2] 。 图3 MK-0616与PCSK9形成复合物,阻断其与LDLR结合 从目前已经公布的研究数据来看...